For citizens

For companies

For medical specialists

Medicines

At its May meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) has completed its review of factor VIII medicines to evaluate the risk of developing inhibitors in patients with haemophilia A who have not previously been treated with these medicines.

Factor VIII is needed for blood to clot normally and is lacking in patients with haemophilia A. Factor VIII products replace the missing factor VIII and help control bleeding. However the body may develop inhibitors as a reaction to these medicines, particularly in patients starting treatment for the first time. This can block the effect of these medicines, so bleeding is no longer controlled.

The review was started following publication of a study which concluded that inhibitors develop more frequently in patients receiving recombinant factor VIII medicines than in those receiving plasma-derived factor VIII medicines. The PRAC concluded that there is no clear and consistent evidence of a difference in inhibitor development between the two classes of factor VIII medicines.

More information is available below:

PRAC concludes there is no clear and consistent evidence of a difference in inhibitor development between classes of factor VIII medicines

EMA reviews diabetes medicine canagliflozin

Review follows data on toe amputations in ongoing study

The European Medicines Agency (EMA) has started a review of the diabetes medicine canagliflozin after an increase in amputations, mostly affecting toes, was observed in an ongoing clinical trial called CANVAS. Cases of lower limb amputation occurred in both the canagliflozin and placebo groups in the trial and the possibility that canagliflozin increases lower limb amputations is currently not confirmed. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has requested more information from the company to assess whether canagliflozin causes an increase in lower limb amputations and whether any changes are needed in the way this medicine is used in the EU.

More information on this is included in the hyperlink below:

EMA reviews diabetes medicine canagliflozin

Medicinal products without prescription in the Republic of Bulgaria to date 28.02.2011

The present list do not include medicinal products with expired authorization, although in the country they can be sold until exhaustion of the actual quantities, but not more than one year from the expiration date of the marketing authorization (in accordance with Art. 55, Para. (6) of LMPHM).

In the event of a favorable opinion on the marketing authorization renewal procedure, they are going to be added to the list.

Drugs without prescription

On ascertainment of inaccuracies and omissions please call: +359 2 890 34 11 +359 2 890 34 11

Last update of the list 20.03.2017.